Vectors that repress heterologous promoter activity
AssigneeGSF-Forschungszentrum Fuer Umwelt und Gesendheit GmbH
InventorsWalter H. Günzburg, Brian Salmons
Life of this patent
Estimating the term…
Abstract
The invention refers to a novel recombinant vectors useful for gene therapy of viral infections and of diseases associated with B and T cells. The present invention relates, furthermore, to novel usages of the two products of the open reading frame of mouse mammary tumour virus.
Claims44
A recombinant vector comprising, mouse mammary tumor virus sequences which consist of a mouse mammary tumor virus long terminal repeat open reading frame and a naf activity sequence, wherein said naf activity sequence is between an R region of a 5′ long terminal repeat and a 3′ end of a gag gene of the mouse mammary tumor virus thereby including a splice donor site which is in addition to the splice donor site at the 5′ end of the gag gene, and wherein the remainder of the vector is derived from a vector other than a mouse mammary tumor virus.
A recombinant retroviral vector which is capable of undergoing promoter conversion and is replication-defective comprising, in operable linkage,
- a) a 5′ long terminal repeat region comprising the structure U3-R-U5 site, derived from a vector other than a mouse mammary tumor virus;
- b) mouse mammary tumor virus sequences consisting of an open reading frame having naf activity derived from a mouse mammary tumor virus long terminal repeat and a naf activity sequence, wherein said naf activity sequence is between an R region of a 5′ long terminal repeat and a 3′ end of a gag gene of the mouse mammary tumor virus thereby including a splice donor site which is in addition to the splice donor site at the 5′ end of the gag gene;
- c) optionally, at least one sequence encoding a peptide selected from the group consisting of:
- β-galactosidase, neomycin, alcohol dehydrogenase, puromycin, hypoxanthine phosphoribosyl transferase (HPRT), hygromycin, secreted alkaline phosphatase, Herpes Simplex Virus thymidine kinase, cytosine deaminase, guanine phosphoribosyl transferase (gpt), cytochrome P 450, cell cycle regulatory proteins, tumor suppressor proteins, antiproliferation proteins, and cytokines;
- and
- d) a 3′ long terminal repeat region derived from a vector other than a mouse mammary tumor virus comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence carrying at least one unique restriction site.
A mouse mammary tumor virus vector comprising a mouse mammary tumor virus long terminal repeat open reading frame, a naf activity sequence, wherein said naf activity sequence consists of a sequence of the mouse tumor virus which is between an R region of a 5′ long terminal repeat and a 3′ end of a gag gene of the mouse mammary tumor virus thereby including a splice donor site which is in addition to the splice donor site at the 5′ end of the gag gene and non-functional mouse mammary tumor virus pol and env genes.
A mouse mammary tumor virus recombinant retroviral vector which is capable of undergoing promoter conversion and is replication-defective comprising, in operable linkage,
- a) a 5′ long terminal repeat region comprising the structure U3-R-U5, derived from a vector other than a mouse mammary tumor virus;
- b) mouse mammary tumor virus sequences consisting of an open reading frame having naf activity derived from a mouse mammary tumor virus long terminal repeat, a naf activity sequence wherein said naf activity sequence is between an R region of a 5′ long terminal repeat and a 3′ end of the gag gene of the mouse mammary tumor virus thereby including a splice donor site which is in addition to the splice donor site at the 5′ end of the gag gene, and non-functional mouse mammary tumor virus pol and env genes;
- c) optionally, at least one sequence encoding a peptide selected from the group consisting of:
- β-galactosidase, neomycin, alcohol dehydrogenase, puromycin, hypoxanthine phosphoribosyl transferase (HPRT), hygromycin, secreted alkaline phosphatase, Herpes Simplex Virus thymidine kinase, cytosine deaminase, guanine phosphoribosyl transferase (gpt), cytochrome P 450, cell cycle regulatory proteins, tumor suppressor proteins, antiproliferation proteins, and cytokines;
- and
- d) a 3′ long terminal repeat region derived from a vector other than a mouse mammary tumor virus comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence carrying at least one unique restriction site.
An isolated host cell comprising an MMTV-LTR ORF and a sequence of an MMTV gag gene with naf activity, said sequences being introduced by a non-MMTV construct into said host cell, wherein the non-MMTV construct comprises MMTV sequences which consist of the MMTV-LTR ORF and a naf activity sequence, wherein said naf activity sequence is between an R region of a 5′ long terminal repeat and a 3′ end of a gag gene of the mouse mammary tumor virus thereby including a splice donor site which is in addition to the splice donor site at the 5′ end of the gag gene.
An isolated host cell comprising an MMTV-LTR ORF, a sequence of an MMTV gag gene with naf activity, and non-functional MMTV pol and env genes.
A method for repressing activity of a viral promoter other than a MMTV promoter in cells in which said viral promoter is present, comprising
- a). introducing a MMTV naf activity sequence into the cells wherein the naf activity sequence consists of a mouse mammary tumor virus long terminal repeat open reading frame and a gag gene of a mouse mammary tumor virus, and said gag sequence is between an R region of a 5′ long terminal repeat and a 3′ end of the gag gene of the mouse mammary tumor virus;
- and
- b). maintaining the cells under conditions in which the naf sequence is expressed, thereby repressing activity of the viral promoter,
- wherein the viral promoter is repressed by a naf activity sequence,.
Dependencies are inferred from the claim text.